Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1057 to 1061 of 1061 entries
Sorted by: Best Match Show Resources per page
Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.

Cancer chemotherapy and pharmacology

Otani T, Yamaguchi K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
PMID: 34350479
Cancer Chemother Pharmacol. 2021 Nov;88(5):857-865. doi: 10.1007/s00280-021-04341-y. Epub 2021 Aug 04.

PURPOSE: Cytotoxic chemotherapy-induced lung injury is a fatal complication in patients with lung cancer and interstitial lung disease (ILD). We aimed to evaluate the association between hyperglycemia and this form of lung injury in patients with lung cancer concomitant...

Cite
Otani T, Yamaguchi K, Nakao S, et al. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease. Cancer Chemother Pharmacol. 2021;88(5):857-865doi: 10.1007/s00280-021-04341-y.
Otani, T., Yamaguchi, K., Nakao, S., Sakamoto, S., Horimasu, Y., Masuda, T., Miyamoto, S., Nakashima, T., Iwamoto, H., Fujitaka, K., Hamada, H., & Hattori, N. (2021). Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease. Cancer chemotherapy and pharmacology, 88(5), 857-865. https://doi.org/10.1007/s00280-021-04341-y
Otani, Toshihito, et al. "Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease." Cancer chemotherapy and pharmacology vol. 88,5 (2021): 857-865. doi: https://doi.org/10.1007/s00280-021-04341-y
Otani T, Yamaguchi K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease. Cancer Chemother Pharmacol. 2021 Nov;88(5):857-865. doi: 10.1007/s00280-021-04341-y. Epub 2021 Aug 04. PMID: 34350479.
Copy Download .nbib Format: NLM
Accelerated decline in lung function in adults with a history of remitted childhood asthma.

The European respiratory journal

Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N.
PMID: 34588191
Eur Respir J. 2022 Jan 13;59(1). doi: 10.1183/13993003.00305-2021. Print 2022 Jan.

BACKGROUND: A significant number of children with asthma show remission in adulthood. Although these adults are often diagnosed with COPD in later life, the effect of clinically remitted childhood asthma on the decline in lung function during adulthood is...

Cite
Miura S, Iwamoto H, Omori K, et al. Accelerated decline in lung function in adults with a history of remitted childhood asthma. Eur Respir J. 2022;59(1)doi: 10.1183/13993003.00305-2021.
Miura, S., Iwamoto, H., Omori, K., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Masuda, T., Miyamoto, S., Nakashima, T., Fujitaka, K., Hamada, H., Yokoyama, A., & Hattori, N. (2022). Accelerated decline in lung function in adults with a history of remitted childhood asthma. The European respiratory journal, 59(1), . https://doi.org/10.1183/13993003.00305-2021
Miura, Shinichiro, et al. "Accelerated decline in lung function in adults with a history of remitted childhood asthma." The European respiratory journal vol. 59,1 (2022). doi: https://doi.org/10.1183/13993003.00305-2021
Miura S, Iwamoto H, Omori K, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Fujitaka K, Hamada H, Yokoyama A, Hattori N. Accelerated decline in lung function in adults with a history of remitted childhood asthma. Eur Respir J. 2022 Jan 13;59(1). doi: 10.1183/13993003.00305-2021. Print 2022 Jan. PMID: 34588191.
Copy Download .nbib Format: NLM
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.

Investigational new drugs

Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T.
PMID: 34495421
Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08.

Few clinical studies have been designed for elderly patients with locally advanced non-small cell lung cancer (NSCLC). We conducted a phase I study to evaluate the tolerability of carboplatin/nab-paclitaxel and concurrent thoracic radiotherapy in elderly patients with locally advanced...

Cite
Omori S, Harada H, Mori K, et al. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2021;40(1):106-114doi: 10.1007/s10637-021-01155-w.
Omori, S., Harada, H., Mori, K., Hisamatsu, Y., Tsuboguchi, Y., Yoshioka, H., Morinaga, R., Daga, H., Kurata, T., & Takahashi, T. (2022). Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational new drugs, 40(1), 106-114. https://doi.org/10.1007/s10637-021-01155-w
Omori, Shota, et al. "Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 106-114. doi: https://doi.org/10.1007/s10637-021-01155-w
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08. PMID: 34495421.
Copy Download .nbib Format: NLM
A case of subfertile cow with structural abnormalities of the X-chromosome.

Annales de genetique et de selection animale

Hanada H, Muramatsu S.
PMID: 22896164
Ann Genet Sel Anim. 1980;12(2):209-13. doi: 10.1186/1297-9686-12-2-209.

No abstract available.

Cite
Hanada H, Muramatsu S. A case of subfertile cow with structural abnormalities of the X-chromosome. Ann Genet Sel Anim. 1980;12(2):209-13doi: 10.1186/1297-9686-12-2-209.
Hanada, H., & Muramatsu, S. (1980). A case of subfertile cow with structural abnormalities of the X-chromosome. Annales de genetique et de selection animale, 12(2), 209-13. https://doi.org/10.1186/1297-9686-12-2-209
Hanada, H, and Muramatsu, S. "A case of subfertile cow with structural abnormalities of the X-chromosome." Annales de genetique et de selection animale vol. 12,2 (1980): 209-13. doi: https://doi.org/10.1186/1297-9686-12-2-209
Hanada H, Muramatsu S. A case of subfertile cow with structural abnormalities of the X-chromosome. Ann Genet Sel Anim. 1980;12(2):209-13. doi: 10.1186/1297-9686-12-2-209. PMID: 22896164; PMCID: PMC2718867.
Copy Download .nbib Format: NLM
MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.

Oral oncology

Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H.
PMID: 34896892
Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. Recently, the use of immune checkpoint inhibitors (ICIs) for drug treatment has been expanding . However, the response rate to...

Cite
Noji R, Kano Y, Hirai H, et al. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021;124:105666doi: 10.1016/j.oraloncology.2021.105666.
Noji, R., Kano, Y., Hirai, H., Onishi, I., Nishii, N., Yoshimura, R., Miyake, S., Ikeda, S., & Harada, H. (2021). MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral oncology, 124105666. https://doi.org/10.1016/j.oraloncology.2021.105666
Noji, Rika, et al. "MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma." Oral oncology vol. 124 (2021): 105666. doi: https://doi.org/10.1016/j.oraloncology.2021.105666
Noji R, Kano Y, Hirai H, Onishi I, Nishii N, Yoshimura R, Miyake S, Ikeda S, Harada H. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncol. 2021 Dec 09;124:105666. doi: 10.1016/j.oraloncology.2021.105666. Epub 2021 Dec 09. PMID: 34896892.
Copy Download .nbib Format: NLM
Showing 1057 to 1061 of 1061 entries